Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

30.01 -0.69 (-2.25%)
Streaming Delayed Price Updated: 12:47 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
ALKERMES PLC (NASDAQ:ALKS) Q3 2025 Earnings Beat Estimates and Drive Stock Surge
Alkermes (ALKS) Q3 2025 earnings crush estimates with a 58% EPS beat and $394.2M revenue. The company raises its full-year 2025 financial guidance. 
Via Chartmill
Topics Earnings
Earnings Scheduled For October 28, 2025
 
Via Benzinga
Preview: Alkermes's Earnings
 
Via Benzinga
Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups
Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors. 
Via Benzinga
Topics Government
Breaking Down Alkermes: 8 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For July 29, 2025
 
Via Benzinga
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
 
Via Benzinga
Earnings Scheduled For May 1, 2025
 
Via Benzinga
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled. 
Via Benzinga
Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for... 
Via MarketMinute
Topics Intellectual Property
Avadel Jumps On $2.1 Billion Takeover Deal. But Buyer, Alkermes, Dives.
The companies are both working in the sleep space, focusing on excessive daytime sleepiness. 
Via Investor's Business Daily
Avadel Stock Rises After Acquisition Offer By Alkermes
Alkermes will buy Avadel for up to $20 per share. 
Via Stocktwits
9 Analysts Assess Alkermes: What You Need To Know
Analysts' ratings for Alkermes (NASDAQ: ALKS) over the last quarter vary from bullish to bearish, as provided by 9 analysts. The following table encapsulates their recent ratings, offering a glimpse... 
Via Benzinga
This Ciena Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
Deep Dive Into Alkermes Stock: Analyst Perspectives (7 Ratings)
 
Via Benzinga
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
ALKERMES PLC (NASDAQ:ALKS) Emerges as a Top Value Pick with Strong Fundamentals and Undervalued Metrics
ALKERMES PLC (ALKS) is a strong value stock with low P/E ratios, high profitability, and a debt-free balance sheet, making it an attractive pick for long-term investors. 
Via Chartmill
Alkermes PLC (NASDAQ:ALKS) Surges 7.8% Pre-Market After Q2 2025 Earnings Beat Revenue and EPS Estimates
Alkermes PLC (ALKS) reported strong Q2 2025 results, beating revenue and EPS estimates, driving a 7.8% pre-market rally. The company reaffirmed full-year guidance, signaling confidence in growth. 
Via Chartmill
Topics Earnings
Alkermes Q2 Sales Up 14 Percent
Via The Motley Fool
Topics Intellectual Property
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study
Alkermes' alixorexton met key endpoints in a Phase 2 trial for narcolepsy type 1, showing strong efficacy and tolerability across all doses. 
Via Benzinga
Expert Outlook: Alkermes Through The Eyes Of 6 Analysts
 
Via Benzinga
Biogen Shares Slip After $46M Research Charge Hits Quarterly Profit
The company anticipates a research expense in Q2 associated with milestone and licensing payments, which will impact both GAAP and non-GAAP earnings per share. 
Via Stocktwits
ALKERMES PLC (NASDAQ:ALKS) – A Potential Undervalued Opportunity in Biopharma
ALKERMES PLC (NASDAQ:ALKS) shows strong profitability and financial health while trading at a discount to peers, making it a potential value opportunity in biopharma. 
Via Chartmill
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday
 
Via Benzinga
Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
 
Via Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.